Market requirements · IT
Italy
AIFA regulates under the Codice del farmaco and has warned on illegal GLP-1 supply through unauthorised channels. Article 115 governs advertising, including social media.
Buyers in this market search for: peptidi all'ingrosso, fornitore peptidi, peptidi da laboratorio.
| Tell us the compounds you need for Italy. | Ask about Italy |
The regime
How compounds are classified in Italy
| Governing law | Legislative Decree 219/2006, the Codice del farmaco, administered by AIFA. Article 115 governs advertising. |
|---|---|
| The regulator's stated position | AIFA issued a warning published 4 September 2025, through the EMA and HMA network, on the sharp rise in illegal medicines marketed as GLP-1 receptor agonists. AIFA states these reach buyers only through illegal channels, meaning unauthorised websites and platforms. |
| A distinction AIFA draws | AIFA asserts that no counterfeit product has entered Italy's legal distribution system. The risk it describes is specifically the unauthorised-website channel, which is precisely the channel an unlicensed supplier of these compounds would occupy. |
| Advertising | Article 115 defines pharmaceutical advertising broadly, including social media promotion, and prohibits public advertising of prescription-only medicines. Administrative fines run from 2,600 to 15,000 euro. |
| Enforcement posture | The framework is in place and AIFA is messaging actively. Published enforcement to date names online sellers rather than wholesale supply. |
| Already supplying Italy? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in Italy needs settled
- Hold the Italian authorisation your intended activity requires before importing.
- Keep promotion out of consumer-facing channels entirely, social media included, since Article 115 covers it explicitly.
- Where a compound is a prescription medicine, the pharmacy channel is the only lawful route.
- Take Italian counsel before supplying into the market.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| AIFA Warning issued through the EMA and HMA network on illegal medicines marketed as GLP-1 receptor agonists | 4 September 2025 | www.aifa.gov.it/en/-/allerta-aumento-farmaci-illegali-vend... |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the Italy brief as a PDF
The regime, the buyer obligations and all 1 sources, dated and linked, in one document you can forward.
Nearby
Southern Europe and nearby markets
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| FR | France | 3 sources | ANSM names compounds individually in its public alerts and has issued sanitary... |
| ES | Spain | 2 sources | AEMPS has issued a formal notice on illegal GLP-1 supply and directs buyers to... |
| PT | Portugal | 5 sources | INFARMED governs medicines under the Estatuto do Medicamento and has flagged a... |
| GR | Greece | 4 sources | EOF issued a public warning in July 2026, and related reporting names specific... |
| AT | Austria | 3 sources | BASG has published a dedicated position holding that a research-use label does... |
Scope
How to use this page
A summary of the published regulatory position in Italy as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into Italy
Do you supply into Italy?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into Italy depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into Italy. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into Italy
Tell us the compounds and your authorisations. We confirm per compound before anything ships.